Filing Flows › Lyell Immunopharma (LYEL) › Q3 2026 › vs Q2 2026
Lyell Immunopharma (LYEL) Q3 2026 vs Q2 2026 (quarter over quarter)
Lyell Immunopharma's revenue fell $1K (-25%) from $4K in Q2 2026 to $3K in Q3 2026.
Lyell Immunopharma, Q3 2026: revenue $3K (-80% year over year), net loss $45.5M, operating cash flow −$34.6M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $3K | $4K | −$1K | -25% |
| Other income, net | $2.8M | $2.6M | $184K | +7% |
| Net loss | $45.5M | $44.8M | $774K | +2% |
| Costs & expenses | $48.3M | $47.3M | $957K | +2% |
| Operating costs | $48.3M | $47.3M | $957K | +2% |
| Operating cash sources | $45.5M | $44.8M | $774K | +2% |
| Depreciation & amortization | $2.1M | $2.2M | −$168K | -8% |
| Share-based compensation | $4.5M | $4.5M | −$18K | -0.4% |
| Working capital & other | $4.4M | $4.1M | $315K | +8% |
| Cash used in operations | $34.6M | $33.9M | $645K | +2% |
| Net loss absorbed | $45.5M | $44.8M | $774K | +2% |
Questions
How much did Lyell Immunopharma's revenue grow quarter over quarter in Q3 2026?
Lyell Immunopharma's revenue fell $1K (-25%) from $4K in Q2 2026 to $3K in Q3 2026.